Phase II study of preoperative bevacizumab, capecitabine and radiotherapy for resectable locally-advanced rectal cancer

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  García, Margarita ^a   Martinez Villacampa, Mercedes ^a   Santos, Cristina ^a   Navarro, Valentin ^a   Teule, Alex ^a   Losa, Ferran ^b   Pisa, Aleydis ^a   Cambray, Maria ^a   Soler, Gemma ^a   Lema, Laura ^a   Kreisler, Esther ^c   Figueras, Agnes ^a   Juan, San ^c   Viñals, Francesc ^a   Biondo, Sebastiano ^c   Salazar, Ramon ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b HOSPITAL GENERAL DE CATALUNYA   (Spain)

^c HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Bevacizumab; Locally advanced; Rectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUOROURACIL; OXALIPLATIN; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN A; ANTINEOPLASTIC AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ABDOMINOPERINEAL AMPUTATION; ADVANCED CANCER; ANOREXIA; ANUS PRURITUS; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPHONIA; DYSURIA; ERYTHEMA; EXTERNAL BEAM RADIOTHERAPY; FEVER; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; ILEUS PARALYTIC; LENGTH OF STAY; LYMPHOCYTOPENIA; MESORECTAL EXCISION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PALLIATIVE THERAPY; POSTOPERATIVE COMPLICATION; PREOPERATIVE PERIOD; PROCTITIS; RADIATION DERMATITIS; RASH; RECTUM CANCER; RECTUM HEMORRHAGE; RECTUM SURGERY; STOMACH PAIN; STOMATITIS; SURGICAL INFECTION; SURVIVAL RATE; TENESMUS; TREATMENT RESPONSE; VASOSPASM; VOMITING; WOUND DEHISCENCE; ADJUVANT CHEMORADIOTHERAPY; AGED; CLINICAL TRIAL; DRUG ADMINISTRATION; FEMALE; MALE; MIDDLE AGED; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PROCEDURES; RADIATION DOSE FRACTIONATION; RECTAL NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAPECITABINE; CHEMORADIOTHERAPY, ADJUVANT; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; RECTAL NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84924066421     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1052-0     Document Type: Article

References (26)

1. MacFarlane JK, Ryall RD, Heald RJ. Mesorectal excision for rectal cancer. Lancet. 1993;341:457-60.
2. Enker WE, Thaler HT, Cranor ML, Polyak T. Total mesorectal excision in the operative treatment of carcinoma of the rectum. J Am Coll Surg. 1995;181:335-46.
3. Havenga K, Enker WE, Norstein J, Moriya Y, Heald RJ, van Houwelingen HC, et al. Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. Eur J Surg Oncol. 1999;25:368-74.
4. Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731-40.
5. Rödel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23:8688-96.
6. Maas M, Nelemans PJ, Valentini V, Das P, Rödel C, Kuo L-J, et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data. Lancet Oncol. 2010;11:835-44.
7. Gérard J-P, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne P-L, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol. 2010;28:1638-44.
8. Aschele C, Cionini L, Lonardi S, Pinto C, Cordio S, Rosati G, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29:2773-80.
9. Goel S, Wong AH-K, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med. 2012;2:a006486.
10. Willett CG, Duda DG, di Tomaso E, Boucher Y, Ancukiewicz M, Sahani DV, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol. 2009;27:3020-6.
11. Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol. 2005;23:8136-9.
12. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10:1-10.
13. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM, et al. REporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer. 2005;41:1690-6.
14. Czito BG, Bendell JC, Willett CG, Morse MA, Blobe GC, Tyler DS, et al. Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys. 2007;68:472-8.
15. Kennecke H, Berry S, Wong R, Zhou C, Tankel K, Easaw J, et al. Pre-operative bevacizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial. Eur J Cancer. 2012;48:37-45.
16. Crane CH, Eng C, Feig BW, Das P, Skibber JM, Chang GJ, et al. Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. Int J Radiat Oncol Biol Phys. 2010;76:824-30.
17. Koukourakis MI, Giatromanolaki A, Tsoutsou P, Lyratzopoulos N, Pitiakoudis M, Kouklakis G, et al. Bevacizumab, capecitabine, amifostine, and preoperative hypofractionated accelerated radiotherapy (HypoArc) for rectal cancer: a Phase II study. Int J Radiat Oncol Biol Phys. 2011;80:492-8.
18. Nogué M, Salud A, Vicente P, Arriví A, Roca JM, Losa F, et al. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist. 2011;16:614-20.
19. Velenik V, Ocvirk J, Music M, Bracko M, Anderluh F, Oblak I, et al. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. Radiat Oncol. 2011;6:105.
20. Dipetrillo T, Pricolo V, Lagares-Garcia J, Vrees M, Klipfel A, Cataldo T, et al. Neoadjuvant bevacizumab, oxaliplatin, 5-fluorouracil, and radiation for rectal cancer. Int J Radiat Oncol Biol Phys. 2012;82:124-9.
21. Gasparini G, Torino F, Ueno T, Cascinu S, Troiani T, Ballestrero A, et al. A phase II study of neoadjuvant bevacizumab plus capecitabine and concomitant radiotherapy in patients with locally advanced rectal cancer. Angiogenesis. 2012;15:141-50.
22. Resch G, De Vries A, Öfner D, Eisterer W, Rabl H, Jagoditsch M, et al. Austrian Breast and Colorectal Cancer Study Group: Preoperative treatment with capecitabine, bevacizumab and radiotherapy for primary locally advanced rectal cancer-a two stage phase II clinical trial. Radiother Oncol. 2012;102:10-3.
23. Spigel DR, Bendell JC, McCleod M, Shipley DL, Arrowsmith E, Barnes EK, et al. Phase II study of bevacizumab and chemoradiation in the preoperative or adjuvant treatment of patients with stage II/III rectal cancer. Clin Colorectal Cancer. 2012;11:45-52.
24. Landry JC, Feng Y, Cohen SJ, Staley 3rd CA, Whittington R, Sigurdson ER, et al. Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECOG 3204. Cancer. 2013;119:1521-7.
25. Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol. 1999;17:2396.
26. Willett CG, Duda DG, Ancukiewicz M, Shah M, Czito BG, Bentley R, et al. A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. Oncologist. 2010;15:845-51.